Results 81 to 90 of about 25,087 (209)

Minimal residual disease is an independent predictor for 10-year survival in CLL [PDF]

, 2016
Minimal residual disease (MRD) negativity, defined as
Abraham Varghese, Abrisqueta, Andy C. Rawstron, Bosch, Böttcher, Chi Doughty, Darren J. Newton, Dreger, Eichhorst, Fischer, Goede, Hallek, Landau, Ma, Marwan Kwok, Moreno, Moreton, Nadeu, Paul A. S. Evans, Paul Moreton, Peter Hillmen, Pettitt, Rawstron, Rawstron, Rawstron, Rossi, Santacruz, Sheila J. M. O’Connor, Strati, Thompson   +29 more
core   +1 more source

Semi‐mechanistic population PK/PD model to aid clinical understanding of myelodysplastic syndromes following treatment with Venetoclax and Azacitidine

CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 448-459, March 2025.
Abstract Myelodysplastic syndromes (MDS) represent a group of bone marrow disorders involving cytopenias, hypercellular bone marrow, and dysplastic hematopoietic progenitors. MDS remains a challenge to treat due to the complex interplay between disease‐induced and treatment‐related cytopenias.
Neha Thakre, Corinna Maier, Jiuhong Zha, Benjamin Engelhardt, Johannes E. Wolff, Sven Mensing   +5 more
wiley   +1 more source

Small molecules, big targets: drug discovery faces the protein-protein interaction challenge. [PDF]

, 2016
Protein-protein interactions (PPIs) are of pivotal importance in the regulation of biological systems and are consequently implicated in the development of disease states.
A Ciulli, A Degterev, A Oberstein, A Patel, A Patel, A Shaginian, A Turnbull, A Winter, AA Bogan, AA Lugovskoy, AB Mahon, AC Braisted, AD Morley, AF Donnell, AG Coyne, AJ Souers, AL Jochim, AM Petros, AM Petros, Andrew R. Bayly, AP Higueruelo, AR Bayly, AV Follis, B Ku, B Lehner, B Ma, B Padmanabhan, BC Raimundo, BE Sleebs, BL Grasberger, C Tse, C Zhuang, CA Lepre, CD Thanos, CG Wilson, CH Arrowsmith, CH Kenny, Chris Abell, CQ Wei, CQ Wei, D Cox, D Grimme, D Marcotte, D Rognan, D Seebach, D Szklarczyk, DA Erlanson, DC Fry, DE Scott, DE Scott, DI Hammoudeh, DJ Craik, DJ Huggins, DK Johnson, Duncan E. Scott, EF Lee, EF Lee, EF Lee, F Christ, F Cossu, F Falchi, FB Sheinerman, FP Davis, G Wang, G Zimmermann, GR Bickerton, H Jhoti, H Jubb, H Karatas, H Sun, H Wu, H Yin, H Zhou, HL Perez, HP Sun, HY Sun, I Monfardini, I Navratilova, I Van Molle, IJ Enyedy, J Hyde, J Liu, JA Kritzer, JA Wells, JB Baell, JC Fuller, JD Sadowsky, JG Allen, JL Wang, JM Davis, John Skidmore, JW Huang, JW Tilley, K Sauve, KI Tong, L Chen, L Hu, L Pellegrini, LD Walensky, LD Walensky, LK Henchey, LM Meireles, LT Vassilev, M Bruncko, M Rickert, M Sattler, M Vogler, M Whittaker, MC Lo, MC Smith, MD Wendt, MJ Basse, MJ de Vega, ML Stewart, MR Arkin, MR Arkin, N Sugaya, O Ichihara, O Keskin, O Keskin, O Mirguet, P Chakrabarti, P Filippakopoulos, P Filippakopoulos, P Mukherjee, P Sledz, P Walter, PJ Hajduk, PJ Hajduk, PJ Real, PW White, Q Cai, Q Chu, QC Zhang, R Hancock, R Hancock, RF Kester, RJ Bienstock, RJ Robb, S Barelier, S Ducki, S Ferrari, S Fletcher, S Fletcher, S Jones, S Miller, SC Lo, SD Furdas, SM Biros, SM Srinivasula, SP Brown, T Clackson, TA Larsen, TG Davies, TJ Blackburn, TK Oost, TL Blundell, TL Blundell, TS Peat, VS Rao, W Antuch, WA Loughlin, WB Turnbull, X Morelli, XQ Liu, Y Chen, Y Huang, Y Tanaka, Y Zhao, YS Tan, Z Hu, ZY Jiang   +171 more
core   +2 more sources

Genocopy of EVI1‐AML with paraneoplastic diabetes insipidus: PRDM16 overexpression by t(1;2)(p36;p21) and enhancer hijacking

British Journal of Haematology, EarlyView.
Summary Diabetes insipidus (DI) in patients with acute myeloid leukaemia (AML) and chromosome 3q alterations (EVI1/PRDM3/MECOM overexpression) constitutes a poorly understood paraneoplasia. A 44‐year‐old patient presented with clinical and morphological features of this syndrome but, surprisingly, disclosed the rare translocation t(1;2)(p36;p21), with ...
Julian List, Etienne Sollier, Fiona Brown‐Burke, Katherine Kelly, Dietmar Pfeifer, Valeria Shlyakhto, Kristina Maas‐Bauer, Milena Pantic, Christoph Plass, Michael Lübbert   +9 more
wiley   +1 more source

On BH3 mimetics and Ca2+ signaling [PDF]

, 2017
BH3 mimetics are anticancer agents that reproduce the spatial arrangement of the BH3 domain of Bcl-2 family proteins. Just like the BH3-only proteins, these compounds bind to the hydrophobic cleft of the pro-survival Bcl-2 members such as Bcl-2 or Bcl-xL,
Ferdek, Pawel, Jakubowska, Monika
core   +1 more source

Hot-spot analysis for drug discovery targeting protein-protein interactions [PDF]

, 2018
Introduction: Protein-protein interactions are important for biological processes and pathological situations, and are attractive targets for drug discovery. However, rational drug design targeting protein-protein interactions is still highly challenging.
Fernández-Recio, Juan, Rosell, Mireia
core   +2 more sources

Venetoclax combined with cladribine, idarubicin, cytarabine (CLIA‐VEN) results in higher remission rates over conventional 7 + 3 chemotherapy without increased toxicity in newly diagnosed acute myeloid leukaemia

British Journal of Haematology, EarlyView.
Summary Induction chemotherapy in fit de novo acute myeloid leukaemia (AML) patients has historically combined an anthracycline with standard‐dose cytarabine (‘7 + 3’) despite complete response (CR) rates of 50%–70%. In May 2023, our institution adopted the utilization of cladribine, cytarabine, idarubicin and venetoclax (CLIA‐VEN) for intensive ...
Benjamin J. Lee, Shawn P. Griffin, Jean Doh, Anthony Quach, Yujiao Sun, Piyatida Chumnumsiriwath, Stefan O. Ciurea, Jorge Ramos‐Perez, Polina Bellman, Deepa Jeyakumar, Piyanuch Kongtim, Kiran Naqvi   +11 more
wiley   +1 more source

Comorbidities and mutations including single‐ and multihit TET2 mutations in relation to outcome in chronic myelomonocytic leukaemia—A population‐based study

British Journal of Haematology, EarlyView.
In a population‐based cohort of 149 chronic myelomonocytic leukaemia (CMML) patients, multihit TET2 mutation was associated with older age, lower LDH and less leucocytosis. We found no association with autoimmune disease or thrombosis. Patients with multihit TET2 mutation had a significantly longer overall survival than the patients without or with one
Matilda Kjellander Kynning, Ebba Westerberg, Linda Forsell, Maria Creignou, Daniel Moreno Berggren, Bianca Tesi, Elsa Bernard, Elli Papaemmanuil, Yasuhito Nannya, Lucia Cavelier Franco, Davide Valentini, Eva Hellström Lindberg, Seishi Ogawa, Elisabeth Ejerblad, Johanna Ungerstedt   +14 more
wiley   +1 more source

Inhibition of FOXM1 Synergizes with BH3 Mimetics Venetoclax and Sonrotoclax in Killing Multiple Myeloma Cells through Repressing MYC Pathway

Advanced Science
Relapsed and refractory multiple myeloma (RRMM) remains the leading cause of MM mortality. FOXM1 is strongly associated with RRMM, making it a compelling therapeutic target.
Zhi Wen, Yidan Wang, Kathryn C. Fox, Adam M. Bissonnette, Luke F. Moat, Terrie E. Kitchner, Kelsey Springstroh, Sung Hoon Kim, Dagna S. Sheerar, Patcharon Tanawattanacharoen, Chady A. Leon, Seth O. Fagbemi, John A. Katzenellenbogen, Scott J. Hebbring, Benita S. Katzenellenbogen, Siegfried Janz, Adedayo A. Onitilo   +16 more
doaj   +1 more source

Gilteritinib overcomes primary resistance to venetoclax in a patient with FLT3 wild-type refractory/relapsed AML: Case report and exploration of possible mechanisms

Heliyon
Venetoclax, a selective BCL-2 inhibitor, has shown superior efficacy in the treatment of AML. Nevertheless, some AML patients with AML1-ETO respond poorly to venetoclax treatment.
Man Li, Xiawan Yang, Yaonan Hong, Qi Liu, Yingying Shen, Tonglin Hu, Yiping Shen, Guoyin Kai, Dijiong Wu   +8 more
doaj   +1 more source